- In October 2024, Carl Zeiss Microscopy, LLC, announced a partnership with Ultivue Inc. to co-market Ultivue's multiplex biomarker assays for tissue phenotyping, which will be integrated with the ZEISS Axioscan whole slide imaging system for data acquisition and analysis. This collaboration aims to provide a comprehensive solution for tissue preparation, image acquisition, and analysis, benefiting researchers in cancer biology, immunology, drug development, and various sectors including academia, biotech, pharma, and CROs
- In September 2024, Lunaphore, a Swiss life sciences firm specializing in technology for spatial biology, and Nucleai, a pioneer in AI-driven spatial biology for precision medicine, revealed a collaboration focused on enhancing the discovery of novel biomarkers and drug targets. This partnership will leverage advanced spatial imaging and machine learning technologies to unlock valuable insights from pathology data
- In May 2024, Illumina Inc. announced that it would present part of its latest research at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 31 to June 4. The presentations will feature data from several studies conducted in partnership with Labcorp, highlighting evidence that supports the use of comprehensive genomic profiling (CGP) over single gene testing (SGT). Additionally, Illumina will present the latest findings related to its molecular residual disease (MRD) assay, which is currently in development alongside major collaborators. A total of 14 abstracts from Illumina were accepted for the conference
- In April 2024, Merck announced its plan to acquire Mirus Bio for USD 600 million. Based in Madison, Wisconsin, Mirus Bio specializes in developing and selling transfection reagents. These reagents, including Mirus Bio's TransIT-VirusGEN®, facilitate the entry of genetic material into cells, playing a crucial role in the creation of viral vectors for cell and gene therapies
- In April 2021, Abcam, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd., announced an expansion of its strategic partnership aimed at developing and commercializing essential companion and in vitro diagnostic kits. This collaboration is focused on empowering MEDx to provide advanced diagnostic solutions in the Chinese market, underscoring both organizations' commitment to advancing precision medicine and improving diagnostic capabilities to meet healthcare needs in China
Frequently Asked Questions
The market is segmented based on Segmentation, By Component (Instruments, Software, and Services), Application (Drug Safety, Oncology Studies, and Genetic Characterization Studies), Imaging Techniques (Immuno Fluorescence Assay, Tissue Microarray Assay, Immunohistochemistry Assay, Fluorescent in the Situ Hybridization Assay, and Toponome Imaging System), End-User (Research Institutes Government & Private, Clinical Labs, and Pharmaceutical & Biotechnology) – Industry Trends and Forecast to 2031
.
The Global Multiplex Biomarker Imaging Market size was valued at USD 521.85 USD Million in 2023.
The Global Multiplex Biomarker Imaging Market is projected to grow at a CAGR of 12.1% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
